大腸がん診断薬・治療薬の世界市場 - 成長・動向・予測
Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
|発行||Mordor Intelligence LLP||商品コード||353905|
|出版日||ページ情報||英文 113 Pages
|大腸がん診断薬・治療薬の世界市場 - 成長・動向・予測 Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日: 2019年04月01日||ページ情報: 英文 113 Pages||
当レポートでは、世界の大腸がん向け診断薬および治療薬の市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、市場規模の動向見通し (今後6年間分)、モダリティ (診断／治療法別) および地域別の詳細動向、市場競争の動き (各種資本取引など)、主要企業のプロファイルといった情報を取りまとめてお届けいたします。
The colorectal cancer diagnostics and therapeutics market are expected to register a CAGR of nearly 4.6% during the forecast period, 2019-2024.
Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, and is any form of cancer that affects the colon and the rectum. The report tracks revenue generated by therapeutics used for the management of colorectal cancer, along with various screening tests, kits, and medical devices used for the diagnosis of colorectal cancer.
Immunotherapy Blockbusters to Remain a Significant Revenue Source For Leading Players Due to Label Expansions Despite Approaching Patent Expiry.
Bevacizumab (Avastin) is a monoclonal antibody that prevents tumors from growing in blood vessels, by antagonizing vascular endothelial growth factor (VEGF), which is a substance released by tumors to stimulate new blood vessel formation. The FDA approved a labeling extension for bevacizumab, administered in combination with intravenous 5-fluorouracil-based chemotherapy, for the second-line treatment of metastatic carcinoma of the colon or rectum. The approval of cyramza (ramucirumab) for second-line Avastin pre-treated metastatic setting, in 2016, is expected to propel the growth of the colorectal cancer drugs market, in the future.
The United States is Expected to Retain Largest Market Share During the Forecast Period
Geographically, the United States holds the largest market share with respect to demand and revenue. In 2017, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States based on the estimates by the American Cancer Society. These estimates indicate that colorectal cancer is increasing its prevalence in the United States, which is in turn, leading to the growth of the market. The Asia-Pacific is also expected to witness a strong growth pattern in the coming years, with China and India showing rapid progress. In 2015, Roche signed an agreement with an insurance company in Shenzhen City. The Chinese people were among the first few to approve Avastin for reimbursement. This is expected to increase access to colorectal cancer therapeutics in China.
Several large drug and equipment manufacturers exist within the global colorectal cancer diagnostic and therapeutics market. Moreover, several new biotech firms are also active in the therapeutics segment. Key players in the market include Abbott Laboratories, Beckman Coulter, Clinical Genomics, Companion DX, EDP Biotech, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, Quest Diagnostics, Siemens Healthineers, and VolitionRX, among others.